---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021834"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:39:28.764144+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q3 2022: Cash $519M, $15M revenue; FDA positive feedback on FT516 RMAT; pipeline progress

## Summary
- Cash and investments $519.1M; Q3 revenue $15.0M from Janssen/ONO collaborations; R&D expense $79.8M.
- Positive FDA feedback under FT516 RMAT for clonal master iPSC bank and potential registrational study design; CMC meeting set for December.
- Enrollment ongoing for FT596+R three-dose escalation at 1.8B cells/dose for R/R BCL; activating community sites for FT596+R-CHOP in newly-diagnosed aggressive BCL.
- Janssen exercised option for second iPSC-derived CAR NK product targeting undisclosed hematologic malignancy antigen; FT555 (GPRC5D) IND candidate for MM to be presented at ASH.
- 14 abstracts selected for ASH and 12 for SITC, including interim Phase 1 data for FT576 (MM), FT819 (BCL), FT536/FT538 (solid tumors).

## SEC filing metadata
- accession: 0000950170-22-021834
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017022021834/0000950170-22-021834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017022021834/fate-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021834
- JSON: https://secwatch.observer/filing/0000950170-22-021834.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021834.txt

## Key facts
- Earnings Releases
  FATE THERAPEUTICS INC reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017022021834/0000950170-22-021834-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.